AUS
NZ
UK
CA
USA
IND
Highlights
Corcept Therapeutics (CORT) shares increased by 5.5% in the latest trading session, closing at $49.75, driven by robust trading volume.
The company’s marketed drug, Korlym, is experiencing strong demand, while a new drug application for relacorilant is anticipated later in the fourth quarter of 2024.
Corcept is projected to report quarterly earnings of $0.27 per share, with revenues anticipated to rise by 39.3% compared to the same quarter last year.
Corcept Therapeutics (NASDAQ:CORT) has seen its shares rise by 5.5% in the most recent trading session, closing at $49.75, bolstered by significantly higher trading volume than usual. This surge comes on the heels of a 15.3% gain over the past four weeks, indicating growing investor interest.
The company’s sole marketed drug, Korlym, which is approved for treating Cushing's syndrome, is currently witnessing robust demand, contributing positively to the company's growth trajectory. In addition, Corcept plans to file a new drug application for its lead candidate, relacorilant, aimed at treating Cushing’s syndrome. This upcoming filing, anticipated later in the fourth quarter of 2024, may be a significant factor in the recent increase in share price, reflecting confidence in the company's pipeline and future potential.
For the upcoming quarterly earnings report, Corcept is projected to report earnings of $0.27 per share, reflecting a slight year-over-year decline of 3.6%. Meanwhile, revenue is expected to reach $172.11 million, indicating a substantial growth of 39.3% compared to the same quarter last year.
While earnings and revenue growth forecasts are critical in assessing stock potential, research suggests a strong correlation between earnings estimate revisions and near-term stock price movements. Notably, the consensus EPS estimate for Corcept has remained stable over the past 30 days. Typically, a stock's price does not maintain an upward trajectory without accompanying trends in earnings estimate revisions.
Corcept currently holds a Zacks Rank of #1 (Strong Buy), positioning it favorably within the Zacks Medical - Drugs industry. Another company in the same sector, Amneal Pharmaceuticals (AMRX), closed the last trading session with a modest increase. Amneal also carries a Zacks Rank of #1 but has experienced a decline in share performance over the past month.
As Corcept Therapeutics continues to advance its strategic initiatives, stakeholders will be attentive to how recent gains may translate into sustained strength in the future.
